Patients with pain in their legs when walking and/or resting that is due to lack of blood flow to their legs may be able to join the study. To join the study patients must also have blockages in their leg arteries that meet the study criteria.

All patients in the study will have treatment with the Thor system. During the procedure, the doctor will take x-ray pictures of the leg arteries. They may also use other treatments such as angioplasty balloons, drug-coated balloons, stents, and filters that collect blood clots, if needed.

Patients treated with the Thor system will be watched until they are ready to go home or up to 24 hours after the procedure if they do not go home right away. Before they go home they will have a test to check the blood flow to their legs.

The purpose of this research study is to find out if a new investigational balloon device is effective in treating insufficient blood flow in the legs (also called peripheral arterial disease, PAD). This new balloon device, Magic Touch PTA^TM, is covered with sirolimus and is able to deliver the sirolimus drug to your blood vessels. We hope to learn if the use of a sirolimus coated angioplasty balloon will improve the treatment of insufficient blood flow in the leg.”

The purpose of this trial is to demonstrate an implantable cardiac device system that combines cardiac contractility modulation, also known as CCM, and implantable cardioverter defibrillator (ICD) modules into one device. CCM-D is also known as a “Cardiac Contractility Modulation – Defibrillator.”

The purpose of this trial is to demonstrate 30-day safety and effectiveness outcomes of the KARDION CORY P4 System (study device) in subjects who require hemodynamic support during PCI procedure.

Patients with heart failure often develop enlargement of their heart. This can cause the mitral valve to malfunction. When the enlargement of the heart causes the mitral valve to malfunction, this is called functional mitral regurgitation. The CARILLON Mitral Contour System is an investigational permanent implant developed for the treatment of functional mitral regurgitation (FMR). The implant is placed using a non-surgical (catheter-based) technique in the Coronary Sinus (CS), a vein on the outside of the heart which is adjacent to the mitral valve. This simple procedure is designed to reshape the mitral valve, reduce valve leakage and thus reduce FMR.

Patients with severe, symptomatic AS often receive a minimally invasive procedure known as transcatheter aortic valve replacement (TAVR) to replace their aortic valve. But for the more than two million people in the U.S. living with moderate, symptomatic AS, TAVR is not included in current treatment guidelines. The Medtronic-sponsored EXPAND II Pivotal Trial will, for the first time, evaluate the safety and effectiveness of the company’s Evolut™ PRO+ and Evolut™ FX TAVR prosthetic valves in patients with moderate, symptomatic AS.